Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
AssigneeShire LLC
InventorDavid HACKETT
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of enhancing selective serotonin reuptake inhibitor effects in mammals. In particular, the invention provides methods for treating selective serotonin reuptake inhibitor dependent conditions such as depression. More specifically, the present invention relates to a method of increasing the antidepressant activity of a selective serotonin reuptake inhibitor (“SSRI”) by administering L-lysine-d-amphetamine in combination with an SSRI and to formulates containing the same. In a preferred aspect, the combination is administered in connection with a method of treating depression. One preferred SSRI is escitalopram. The preferred amphetamine prodrug is L-lysine-d-amphetamine.
Claims15
A method of treating depression in a mammal, comprising administering an effective amount of a selective serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof in combination with an amphetamine prodrug, or pharmaceutically acceptable salt thereof to a mammal in need thereof, wherein the selective serotonin reuptake inhibitor is citalopram, escitalopram, paroxetine and sertraline, or a pharmaceutically acceptable salt thereof.
A method of increasing the antidepressant effect of a selective serotonin reuptake inhibitor in a mammal, comprising administering an effective amount of a selective serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an amphetamine prodrug to a mammal in need thereof.
A method enhancing the therapeutic effects of a selective serotonin reuptake inhibitor in a mammal, comprising administering an effective amount of a selective serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof to a mammal having an SSRI-treatable condition in combination with an amount of an amphetamine prodrug which is sufficient to enhance or potentiate the SSRI effects in the mammal.
A kit for use in the treatment of a patient having depression, comprising a selective serotonin reuptake inhibitor selected from the group comprising:
- citalopram, escitalopram, paroxetine and sertraline or a pharmaceutically acceptable salt thereof formulated for administration to the patient and an amphetamine prodrug or a pharmaceutically acceptable salt thereof formulated for administrated to the patient.
Dependencies are inferred from the claim text.